[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Han SL, Cheng J, Zhou HZ, Guo SC, Jia ZR, Wang PF: Surgically treated primary malignant tumor of small bowel: a clinical analysis. World J Gastroenterol; 2010 Mar 28;16(12):1527-32
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgically treated primary malignant tumor of small bowel: a clinical analysis.
  • AIM: To evaluate the clinical presentation, treatment and survival of patients with primary malignant tumor of small bowel (PMTSB).
  • RESULTS: The most common initial clinical features of the patients were intermittent abdominal discomfort or vague abdominal pain (67.4%), abdominal mass (31.2%), bowel obstruction (24.1%), hemotochezia (21.3%), jaundice (16.3%), fever (14.2%), coexistence of bowel perforation and peritonitis (5.7%), coexistence of gastrointestinal bleeding and shock (5.0%), and intraabdominal bleeding (1.4%).
  • Ileum was the most common site of tumor (44.7%), followed by jejunum (30.5%) and duodenum (24.8%).
  • Segmental bowel resection (n = 81) was the most common surgical procedure, followed by right hemi-colectomy (n = 15), pancreaticoduodenectomy (n = 10), and others (n = 19).
  • Twenty-seven adenocarcinoma patients and 13 malignant lymphoma patients received adjuvant chemotherapy with 5-fluorouracil and cyclophosphamide, adriamycin, vincristine and prednisone, respectively.
  • The median survival time of PMTSB patients was 20.3 mo.
  • Gastrointestinal stromal tumor was observed in 80.0% (20/25), 72.0% (18/25) and 36.0% (9/25) of the patients, respectively.
  • CONCLUSION: En bloc resection is the principal therapy for most PMTSB and chemotherapy is the important treatment modality for malignant lymphoma and other malignant tumors of small bowel which cannot be radically removed.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoid Tumor / surgery. Digestive System Surgical Procedures. Gastrointestinal Stromal Tumors / surgery. Intestinal Neoplasms / surgery. Intestine, Small / surgery. Lymphoma / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2005;69(4):290-4 [16282708.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):731-41 [15966194.001]
  • [Cites] Cancer Imaging. 2006;6:209-12 [17208678.001]
  • [Cites] World J Gastroenterol. 2007 Jan 21;13(3):432-7 [17230614.001]
  • [Cites] Ann Diagn Pathol. 2007 Feb;11(1):39-45 [17240306.001]
  • [Cites] Chirurgia (Bucur). 2006 Sep-Oct;101(5):477-81 [17278638.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Mar;19(2):143-9 [17355111.001]
  • [Cites] Arch Surg. 2007 Mar;142(3):229-35 [17372046.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):129-34 [17419246.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2263-9 [17549572.001]
  • [Cites] Arch Surg. 2009 Jul;144(7):670-8 [19620548.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Am J Surg. 2000 Jan;179(1):37-41 [10737576.001]
  • [Cites] Arch Surg. 2000 Jun;135(6):635-41; discussion 641-2 [10843358.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):727-32 [11462914.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Aug;57(2):169-83 [12153595.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] J Gastrointest Surg. 2003 Nov;7(7):925-30 [14592670.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):469-81 [14713260.001]
  • [Cites] Int Surg. 2004 Jan-Mar;89(1):21-6 [15085993.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Surg Clin North Am. 1986 Aug;66(4):779-85 [3738698.001]
  • [Cites] AJR Am J Roentgenol. 1989 May;152(5):995-8 [2705358.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1994 Feb;15(1):46-50 [8082141.001]
  • [Cites] Ann Surg Oncol. 1995 Jan;2(1):26-31 [7834450.001]
  • [Cites] Ann Surg Oncol. 1994 May;1(3):183-8 [7842287.001]
  • [Cites] Ann Surg. 1997 Mar;225(3):262-7 [9060581.001]
  • [Cites] Oncology (Williston Park). 1997 Apr;11(4):529-36; discussion 545, 549-50 [9130275.001]
  • [Cites] Surg Endosc. 1997 Dec;11(12):1153-8 [9373284.001]
  • [Cites] J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91 [9386295.001]
  • [Cites] Br J Cancer. 1999 Jul;80(9):1440-4 [10424748.001]
  • [Cites] World J Surg. 2006 Mar;30(3):391-8; discussion 399 [16479330.001]
  • (PMID = 20333796.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2846261
  •  go-up   go-down


2. Hiraki M, Kitajima Y, Ohtsuka T, Kai K, Miyake S, Koga Y, Mori D, Noshiro H, Tokunaga O, Miyazaki K: Immunohistochemical and molecular genetic analyses of multiple sporadic gastrointestinal stromal tumors. World J Gastrointest Oncol; 2010 Sep 15;2(9):364-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and molecular genetic analyses of multiple sporadic gastrointestinal stromal tumors.
  • A gastroduodenal endoscopic examination revealed no definitive localized lesions.
  • However, both a large amount of cruor and blood flow from the small intestine into the ascending colon was observed during the colonoscopic examination.
  • At least three tumors, believed to originate from the small intestine, were detected by abdominal computed tomography.
  • Based on these findings, multiple and hemorrhagic small intestinal tumors were diagnosed and surgical treatment of the tumors planned.
  • During the celiotomy, twelve tumors were found in the small intestine.
  • Intestinal wedge or partial resection was applied.
  • All excised specimens demonstrated morphology of a submucosal tumor and the largest tumor had a delle with coagulation on the mucosal face.
  • The immunohistochemical examination revealed that the tumor cells were diffusely positive for KIT and CD34.
  • The myenteric plexus layer of the small intestine was focal-positive for KIT and showed no intestinal cells of Cajal hyperplasia.
  • The tumor sequencing results revealed an identical missense mutation in codon 642 of c-kit exon 13 leading to the replacement of lysine by glutamic acid and a silent germ-line mutation in exon 12 of the PDGFRA gene concerning whole blood, normal mucosa and tumors.
  • We concluded that the current subject was categorized as having multiple sporadic-type gastrointestinal stromal tumor with identical mutational types.
  • Although the patient did not receive any adjuvant chemotherapy, there has been no sign of recurrence over the 3 years since the surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160808.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999140
  • [Keywords] NOTNLM ; Gastrointestinal stromal tumor / Germline mutation / K642E / KIT / Missense mutation / Platelet-derived growth factor receptor a / Surgery / c-kit
  •  go-up   go-down


3. Yeh CN, Chen TW, Wu TJ, Hsueh S, Jan YY: Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate. World J Gastroenterol; 2006 Jun 21;12(23):3760-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.
  • METHODS: Thirty-three of 74 (44.6%) small bowel gastrointestinal stromal tumor (GIST) patients who developed recurrence after curative resection and not treated with Glivec were classified as group A patients.
  • Twenty-two advanced small bowel GIST patients treated with Glivec were classified as group B patients.
  • Each tumor in group B patients was investigated for mutations of kit or platelet-derived growth factor alpha (PDGFRA).
  • The mutation type was correlated with clinical outcomes.
  • The anti-tumor effect and safety of Glivec in group B patients were also assessed.
  • RESULTS: Advanced small bowel GIST patients treated with Glivec had substatntially longer post-recurrence survival and higher overall survival rates than those not treated with Glivec.
  • In 13 patients with GISTs harboring exon 11 kit mutations, the partial response rate (PR) was 69.3%, whereas two of three patients with tumors containing an exon 9 kit mutation had an overall response rate (ORR) of 66.7% (not significant).
  • Glivec induces a sustained objective response in more than half of Asian patients with advanced small bowel GISTs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Intestinal Neoplasms / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Exons / genetics. Female. Gene Expression Regulation, Neoplastic. Humans. Imatinib Mesylate. Male. Middle Aged. Mutation. Platelet-Derived Growth Factor / genetics. Prognosis. Prospective Studies. Proto-Oncogene Proteins c-kit / genetics. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Jul 20;19(31):3521-8 [10918610.001]
  • [Cites] Blood. 2000 Aug 1;96(3):925-32 [10910906.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Oct;295(1):139-45 [10991971.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):383-9 [11296107.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):332-9 [12594669.001]
  • [Cites] Int J Cancer. 2003 Nov 1;107(2):317-22 [12949814.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Cancer. 1978 Sep;42(3):1375-84 [81101.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):177-87 [7053814.001]
  • [Cites] Ann Surg. 1987 Dec;206(6):706-10 [3689007.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):68-77 [1731651.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Curr Probl Surg. 1996 Oct;33(10):817-72 [8885853.001]
  • [Cites] Am J Surg. 1997 May;173(5):390-4 [9168073.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):297-305 [9891770.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):377-89 [10199467.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3211-20 [10986053.001]
  • (PMID = 16773696.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Platelet-Derived Growth Factor; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC4087472
  •  go-up   go-down


Advertisement
4. Bettini AC, Beretta GD, Sironi P, Mosconi S, Labianca R: Chemotherapy in small bowel adenocarcinoma associated with celiac disease: a report of three cases. Tumori; 2003 Mar-Apr;89(2):193-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in small bowel adenocarcinoma associated with celiac disease: a report of three cases.
  • Tumors of the small intestine are rare and usually occur in association with genetic disease and chronic intestinal inflammation.
  • We report three cases of small bowel adenocarcinoma in patients affected by celiac disease who received a safe chemotherapy regimen (FOLFOX IV or LV5FU2) after tumor resection.
  • [MeSH-major] Adenocarcinoma / drug therapy. Celiac Disease / complications. Duodenal Neoplasms / drug therapy. Jejunal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12841670.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Kashfi K, Borgo S, Williams JL, Chen J, Gao J, Glekas A, Benedini F, Del Soldato P, Rigas B: Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J Pharmacol Exp Ther; 2005 Mar;312(3):978-88
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NO-donating aspirin (NO-ASA), a novel pharmacological agent currently undergoing clinical testing, consists of ASA to which a nitrate group is covalently linked via a spacer molecule.
  • Treatment for 3 weeks of Min (Apc(min)(/+)) mice, a model of intestinal cancer, with equimolar amounts of meta- and para-NO-ASA decreased the number of tumors in the small intestine by 36 and 59% (P < 0.01), respectively, compared with vehicle-treated controls, thus confirming their in vitro differences in potency.
  • Thus, positional isomerism is critical for the pharmacological properties of NO-ASA against colon cancer and it should be taken into consideration in rational drug design.
  • [MeSH-major] Aspirin / analogs & derivatives. Aspirin / pharmacology. Colonic Neoplasms / drug therapy. Growth Inhibitors / pharmacology. Nitrates / pharmacology. Nitric Oxide Donors / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. HT29 Cells. Humans. Isomerism. Nitric Oxide / secretion. Proliferating Cell Nuclear Antigen / analysis. Structure-Activity Relationship

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15528453.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA92423; United States / NCI NIH HHS / CA / CA92423-S1
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Inhibitors; 0 / N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl ester; 0 / Nitrates; 0 / Nitric Oxide Donors; 0 / Proliferating Cell Nuclear Antigen; 31C4KY9ESH / Nitric Oxide; R16CO5Y76E / Aspirin
  •  go-up   go-down


6. Palmerini E, Fan K, Yang K, Risio M, Edelmann W, Lipkin M, Biasco G: Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/- /Apc1638(N/+) mice. Anticancer Res; 2007 Nov-Dec;27(6B):3807-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The present study examines the effect of piroxicam, a non-steroidal anti-inflammatory drug, on tumor development in Mlh1+/- /Apc1638(N/+) mice, in a preclinical model of human colon cancer.
  • The number, location and volume of tumors, and apoptosis in the flat mucosa were determined in small and large intestine.
  • RESULTS: Piroxicam reduced the number of tumors per mouse by 80% in the small intestine (0.1 vs. 0.5, p < 0.05).
  • In contrast, piroxicam increased tumor incidence (82% vs. 10%, p < 0.01), tumor multiplicity (1.2 vs. 0.1, p < 0.01) and tumor volume (2.1 vs. 0.2 mm3, p < 0.01) in the colon.
  • Apoptosis increased in the epithelium of the small intestine.
  • CONCLUSION: Consistent with the increased apoptosis, piroxicam reduced tumors in the small intestine.
  • [MeSH-major] Colorectal Neoplasms, Hereditary Nonpolyposis / drug therapy. Colorectal Neoplasms, Hereditary Nonpolyposis / pathology. Piroxicam / pharmacology
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Animals. Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Apoptosis / drug effects. Apoptosis / genetics. Disease Models, Animal. Epithelial Cells / drug effects. Epithelial Cells / pathology. Genes, APC. Genetic Predisposition to Disease. Intestine, Small / drug effects. Intestine, Small / pathology. Mice. Mice, Mutant Strains. Nuclear Proteins / genetics. Random Allocation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225536.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-85164
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Mlh1 protein, mouse; 0 / Nuclear Proteins; 13T4O6VMAM / Piroxicam
  •  go-up   go-down


7. Warner RR: Carcinoid case presentation and discussion: the American perspective. Endocr Relat Cancer; 2003 Dec;10(4):489-96
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He had been treated for several years with supportive medications and biotherapy including octreotide and alpha interferon but his tumor eventually progressed and his overall condition was markedly deteriorated when he first sought more aggressive treatment.
  • This consisted of prompt replacement of both tricuspid and pulmonic valves, followed by hepatic artery chemoembolus (HACE) injection and then surgical tumor debulking including excision of the primary tumor in the small intestine.
  • Prophylactic cholecystectomy was also performed and a biopsy of tumor was submitted for cell culture drug resistance testing.
  • This was followed by systemic chemotherapy utilizing the drug (docetaxel) which the in vitro studies suggested as most likely to be effective.
  • His excellent response to this succession of treatments exemplifies the successful application of aggressive sequential multi-modality therapy.
  • [MeSH-major] Carcinoid Heart Disease / pathology. Carcinoid Heart Disease / therapy. Intestinal Neoplasms / pathology. Intestinal Neoplasms / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / pharmacology. Chemoembolization, Therapeutic. Combined Modality Therapy. Heart Valve Prosthesis Implantation. Humans. Male. Middle Aged. Octreotide / pharmacology. Pulmonary Valve / pathology. Pulmonary Valve / surgery. Taxoids / pharmacology. Tricuspid Valve Insufficiency / pathology. Tricuspid Valve Insufficiency / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14713263.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Taxoids; 15H5577CQD / docetaxel; RWM8CCW8GP / Octreotide
  •  go-up   go-down


8. Sethna K, Sugarbaker PH: Localized visceral invasion of peritoneal mesothelioma causing intestinal obstruction: a new clinical presentation. Hepatogastroenterology; 2005 Jul-Aug;52(64):1087-9
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized visceral invasion of peritoneal mesothelioma causing intestinal obstruction: a new clinical presentation.
  • The tumor involved the full thickness of the bowel besides the familiar surface spread which is characteristic of the disease.
  • Intestinal obstruction is a rare or late presentation of mesothelioma.
  • It was the presenting symptom in the present case due to the full thickness infiltration of the small bowel by the tumor.
  • The offending segment was resected and the ascites was treated with intraperitoneal chemotherapy.
  • [MeSH-major] Intestinal Obstruction / etiology. Mesothelioma / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Male. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001635.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


9. Yokoi M, Hosokawa K, Funaki H, Yoshitani S, Kinami S, Omote K, Ueda N, Nakano Y, Kosaka T, Minato H: [A case of retroperitoneal dedifferentiated liposarcoma successfully treated with IFM and CDDP]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2114-6
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery was performed including the tumor, small bowel, and sigmoid resection, and an artificial anus was constructed.
  • Multiple tumors in the peritoneum were noted.
  • Large dark red tumors that were hemorrhagic were resected, but the yellowish tumors were unresectable.
  • Despite VAC chemotherapy (VCR 1.5 mg, ACD 0.5 mg, CPA 900 mg), progressive disease (PD) was noted.
  • As second-line chemotherapy, weekly IFM (2 g)+CDDP (30 mg) was given.
  • Shrinkage of the tumor infiltrates in the artificial anus, decreased abdominal bloating, and improved QOL were observed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liposarcoma / drug therapy. Retroperitoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037341.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


10. Bolanowski M, Jarzab B, Handkiewicz-Junak D, Jeziorski A, Kos-Kudła B, Zajecki W, oraz Pozostali Uczestnicy Konferencji Okragłego Stołu: [Neuroendocrine tumors of the small intestine and the appendix - management guidelines (recommended by The Polish Network of Neuroendocrine Tumors)]. Endokrynol Pol; 2008 Jan-Feb;59(1):87-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine tumors of the small intestine and the appendix - management guidelines (recommended by The Polish Network of Neuroendocrine Tumors)].
  • Polish recommendations regarding management of patients suffering from neuroendocrine tumors of small intestine and appendix are presented.
  • Small intestine, especially ileum represent most common origin of these tumors.
  • Symptoms are atypical, diagnosis could be often accidental.
  • Ultrasound, colonoscopy, capsule endoscopy, baloon enteroscopy, computed tomography, magnetic resonance and somatostatin analogs scintigraphy could be used for the visualization.
  • The treatment of choice in the neuroendocrine tumors of small intestine and appendix is radical or palliative surgery, if possible using endoscopy.
  • Pharmacotherapy consists of biotherapy and chemotherapy.
  • The crucial in biotherapy is somatostatin analogs application, possible in symptomatic treatment of hormonally functioning tumors.
  • This is treatment of choice in carcinoid crisis.
  • Chemotherapy is less successful in disseminated or locally advanced intestinal neuroendocrine tumors, so radioisotope therapy should be considered in each case of unresectable tumor.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / therapy. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / therapy. Practice Guidelines as Topic
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / diagnosis. Appendiceal Neoplasms / therapy. Clinical Competence. Combined Modality Therapy / methods. Endoscopy, Gastrointestinal / methods. Humans. Intestine, Small. Neoplasm Staging. Physical Examination. Poland. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18335403.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Investigator] Bar-Andziak E; Cwikła J; de Herder W; Dzielicki J; Falconi M; Foltyn W; Gaciong Z; Hubalewska-Dydejczyk A; Kowalska A; Krolicki L; Krzyzanowska-Swiniarska B; Kryszałowicz B; Kvols L; Nasierowska-Guttmejer A; O'Toole D; Kunikowska J; Lampe P; Matyja V; Mełen-Mucha G; Milewicz A; Nowak A; Nowakowska-Duława E; Omyła-Staszewska J; Pajak J; Rudzki S; Rydzewska G; Sowinski J; Starzynska T; Strzelczyk J; Sworczak K; Syrenicz A; Szawlowski A; Tomaszewska RA; Wasko-Czopnik D; Wronski M; Zemczak A; Zgliczynski W
  •  go-up   go-down


11. Salamanca J, Nevado M, Martínez-González MA, Pérez-Espejo G, Pinedo F: Undifferentiated carcinoma of the jejunum with extensive rhabdoid features. Case report and review of the literature. APMIS; 2008 Oct;116(10):941-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant rhabdoid tumor, first described in the kidney of young infants, is a rare and highly aggressive neoplasm of controversial histogenesis that has been reported at many other sites, including the gastrointestinal tract.
  • However, malignant rhabdoid tumor of the small intestine is very rare, with only seven cases published to date.
  • Microscopically, the tumor was characterized by neoplastic cells with vesicular nuclei, large nucleoli and abundant eccentric cytoplasm with hyaline globular intracytoplasmic inclusions.
  • Immunohistochemically, the neoplasm coexpressed vimentin and epithelial antigens (AE1/AE3, Cam 5.2, CK34betaE12, CK19 and EMA), most of them showing a peculiar immunostaining pattern in relation to the globular inclusions.
  • The patient received postoperative chemotherapy but died 9 months after surgery.
  • As with tumors at other sites, recognition of rhabdoid morphology in small intestine neoplasms is of significance because the prognosis is extremely poor.
  • [MeSH-major] Carcinoma / pathology. Jejunal Neoplasms / pathology. Liver Neoplasms / secondary. Rhabdoid Tumor / pathology
  • [MeSH-minor] Aged. Anion Exchange Protein 1, Erythrocyte / analysis. Anion Exchange Protein 1, Erythrocyte / metabolism. Biomarkers / analysis. Biomarkers / metabolism. Biopsy. Cell Nucleolus / pathology. Fatal Outcome. Humans. Hyalin / metabolism. Immunohistochemistry. Inclusion Bodies / metabolism. Inclusion Bodies / pathology. Jejunum / metabolism. Jejunum / pathology. Keratins / analysis. Keratins / metabolism. Liver / pathology. Male. Neoplasm Proteins / analysis. Neoplasm Proteins / metabolism. Vimentin / analysis. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19132990.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anion Exchange Protein 1, Erythrocyte; 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / CK-34 beta E12; 0 / Neoplasm Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 8
  •  go-up   go-down


12. Kotake M, Murakami N, Bandou H, Morita K, Koizumi H, Yoshino H, Tawaraya K, Ishiguro K, Kinoshita S, Yamada T: [A case of primary small intestinal cancer accompanied by virchow lymph node metastasis undergoing TS-1 treatment]. Gan To Kagaku Ryoho; 2005 Nov;32(12):1955-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary small intestinal cancer accompanied by virchow lymph node metastasis undergoing TS-1 treatment].
  • Abdominal computed tomography (CT) revealed wall thickening of the small intestine and multiple lymph node metastases.
  • Barium meal study of the small intestine showed circular stenosis.
  • The patient was operated on under a diagnosis of tumor of the small intestine and left neck lymph node swelling.
  • Needle biopsy of the left neck lymph node and partial resection of the small intestine was done without regional lymph node dissection because of Virchow lymph node metastasis.
  • On the resected material a 5 x 4 cm type 2 tumor was identified.
  • The patient received the chemotherapy with TS-1.
  • TS-1(80 mg/body/day) orally administered for 4 weeks followed by a drug-free 2-week period as one course.
  • There were no drug side effects.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Intestinal Neoplasms / drug therapy. Intestine, Small. Lymph Nodes / pathology. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymphatic Metastasis. Neoadjuvant Therapy. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282734.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


13. Auer J, Kirchgatterer A, Berent R, Allinger S, Hinterholzer G, Höbling W, Meindl S, Oppitz P, Kalchmair J, Neuwirth G, Knoflach P: [Gastrointestinal hemorrhage needing blood transfusion as the first manifestation of small bowel carcinoid tumor]. Z Gastroenterol; 2000 Aug;38(8):631-6
Hazardous Substances Data Bank. ACENOCOUMAROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal hemorrhage needing blood transfusion as the first manifestation of small bowel carcinoid tumor].
  • Carcinoid tumors arise from enterochromaffin or enterochromaffin-like cells that are present in the gastrointestinal tract, ovaries, and lungs.
  • Carcinoid syndrome is associated with small intestine carcinoids in about 40%.
  • Common symptoms include intermittent intestinal obstruction with crampy abdominal pain and vomiting, and weight loss.
  • Upper gastrointestinal bleeding with melaena or hematochezia is a relatively rare early symptom of patients with small intestine carcinoid tumors.
  • Laparotomy revealed bleeding from a small submucosal malignant carcinoid tumor in small intestine and multiple large metastases within mesenteric tissue.
  • Segmental resection of small intestine and exstirpation of the metastatic masses was performed.
  • Cytotoxic chemotherapy in this adjuvant setting has not been recommended.
  • Small intestinal carcinoid tumor has to be considered as a rare cause of gastrointestinal bleeding with melaena or hematochezia.
  • Nevertheless, bleeding is a relatively rare early symptom of patients with small intestine carcinoid tumor.
  • [MeSH-major] Blood Transfusion. Carcinoid Tumor / diagnosis. Gastrointestinal Hemorrhage / etiology. Intestinal Neoplasms / diagnosis. Intestine, Small
  • [MeSH-minor] Acenocoumarol / administration & dosage. Acenocoumarol / adverse effects. Aged. Diagnosis, Differential. Humans. Male. Protein S Deficiency / drug therapy. Protein S Deficiency / genetics. Recurrence


14. Hong SH, Koh YH, Rho SY, Byun JH, Oh ST, Im KW, Kim EK, Chang SK: Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol; 2009 Jan;39(1):54-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome.
  • BACKGROUND: Malignant small intestine tumor accounts for 0.1-0.3% of all malignancies.
  • METHODS: We conducted retrospective analysis for the patients with the small intestine adenocarcinoma to explore the clinical characteristics and prognosis.
  • All patients with adenocarcinoma of small intestine diagnosed between March 1997 and March 2007 in the Catholic Medical Center in Korea were identified through the cancer registry.
  • The medical records were reviewed for patient characteristics, treatment and outcome data.
  • Twenty-six patients (49.0%) underwent curative resection and 13 patients receiving adjuvant chemotherapy.
  • Fifteen patients received palliative chemotherapy.
  • Median survival of patients received palliative chemotherapy was 8.0 months (95% CI: 3.5-12.4).
  • CONCLUSIONS: The prognosis of primary adenocarcinoma of small intestine was poor, especially in cases where curative resection could not to be performed.
  • Further study on the methods for early detection and effective systemic chemotherapy should be investigated.
  • [MeSH-major] Adenocarcinoma / pathology. Intestinal Neoplasms / pathology. Intestine, Small / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Korea. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18997182.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


15. Blanchard DK, Budde JM, Hatch GF 3rd, Wertheimer-Hatch L, Hatch KF, Davis GB, Foster RS Jr, Skandalakis JE: Tumors of the small intestine. World J Surg; 2000 Apr;24(4):421-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors of the small intestine.
  • This collective review includes all available case reports and series of smooth muscle (stromal) tumors of the small intestine in the world literature from 1881 to 1996.
  • The peak incidence of smooth muscle tumors in the small intestine in both male and female patients was between the ages of 50 and 59.
  • Computed tomography was found to detect LM and LMS most successfully and had the additional advantage of locating metastatic disease.
  • The jejunum contained the highest numbers of smooth muscle tumors, followed by the ileum and then the duodenum, with malignant lesions in all locations typically attaining larger diameters than benign tumors.
  • For both benign and malignant smooth muscle tumors of the small intestine, surgery remains the treatment of choice, with little efficacy reported for irradiation, chemotherapy, or both.
  • [MeSH-major] Intestinal Neoplasms / classification. Intestine, Small / pathology. Leiomyoma / classification. Leiomyosarcoma / classification
  • [MeSH-minor] Age Factors. Female. Gastrointestinal Hemorrhage / physiopathology. Humans. Incidence. Lymphatic Metastasis. Male. Middle Aged. Sex Factors. Survival Rate. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10706914.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 60
  •  go-up   go-down


16. Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, Shivdasani RA: High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer; 2008 Jul;47(7):591-603
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss.
  • Carcinoid tumors of the small intestine are characterized by an indolent clinical course, secretion of neuropeptides, and resistance to standard cytotoxic chemotherapy.
  • To evaluate the molecular events underlying carcinoid tumorigenesis, we used high-resolution arrays of single nucleotide polymorphisms to study chromosomal gains and losses in 24 primary and metastatic small bowel carcinoid tumors derived from 18 patients.
  • The amplitude of observed gains was modest in comparison to those reported in some other tumor types.
  • One focal region of recurrent gain on 14q mapped to the locus of the gene encoding the antiapoptotic protein DAD1, and immunohistochemical staining confirmed DAD1 protein expression in tumor samples.
  • This detailed study of an uncommon neoplasm provides a basis to investigate putative oncogenes and tumor suppressor genes in intestinal carcinoid tumors.
  • [MeSH-major] Chromosome Aberrations. Intestinal Neoplasms / genetics. Intestine, Small. Liver Neoplasms / genetics. Malignant Carcinoid Syndrome / genetics. Neoplasm Recurrence, Local / genetics

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18383209.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / DAD1 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


17. Kong M, Wang YL, Xu LJ, Teng XD: [Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures]. Zhonghua Bing Li Xue Za Zhi; 2009 Sep;38(9):617-20
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal stromal tumor of small intestine associated with lymph node metastasis: a report of 2 cases with review of literatures].
  • OBJECTIVE: To study the clinicopathologic features of gastrointestinal stromal tumor (GIST) of small intestine with lymph node metastasis and evaluate the respond to imatinib mesylate (Glivec) therapy.
  • METHODS: Two cases of GIST of small intestine associated with lymph node metastasis were collected and investigated by light microscopy and immunohistochemistry.
  • RESULTS: The cases presented as small intestinal mass of irregular shape.
  • Histologically, the tumors consisted of epithelioid and spindled cells, with areas of coagulative necrosis and hemorrhage.
  • Immunohistochemical study showed that the tumor cells were diffusely distributed and strongly positive for CD117.
  • These two cases were all underwent primary chemotherapy with imatinib mesylate and without new tumor was found during follow-up periods (18, 26 months) after operation.
  • CONCLUSIONS: GIST with nodal metastasis is very rare and needs to be distinguished from other soft tissue sarcomas occurring in this site.
  • The responsiveness to imatinib mesylate therapy correlates with the mutation status of c-kit gene.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Mutation. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / metabolism. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Benzamides. Codon. Exons. Follow-Up Studies. Humans. Imatinib Mesylate. Lymphatic Metastasis. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079191.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Codon; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


18. Yokoyama A, Dairaku N, Kusano M, Koshita S, Shimada N, Yamagiwa T, Kojima Y, Ojima T, Ikeya S, Nakayama H, Sugai Y, Hiwatashi N, Asano S: [Two cases of primary unresectable and/or recurrent gastrointestinal stromal tumors of small intestine presenting hemoperitoneum caused by administration of imatinib mesylate]. Nihon Shokakibyo Gakkai Zasshi; 2008 Nov;105(11):1619-26
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of primary unresectable and/or recurrent gastrointestinal stromal tumors of small intestine presenting hemoperitoneum caused by administration of imatinib mesylate].
  • Case1 was a 52-year-old man who had recurrence of postoperative intra-abdominal disseminations from gastrointestinal stromal tumor (GIST) of the jejunum.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / surgery. Hemoperitoneum / chemically induced. Piperazines / adverse effects. Piperazines / therapeutic use. Pyrimidines / adverse effects. Pyrimidines / therapeutic use
  • [MeSH-minor] Aged. Benzamides. Combined Modality Therapy. Digestive System Surgical Procedures. Emergencies. Fatal Outcome. Humans. Imatinib Mesylate. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987447.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 19
  •  go-up   go-down


19. Quintas-Cardama A, Fraga M, Antunez J, Forteza J: Primary extramedullary myeloid tumor of the breast: a case report and review of the literature. Ann Hematol; 2003 Jul;82(7):431-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extramedullary myeloid tumor of the breast: a case report and review of the literature.
  • Primary extramedullary myeloid tumors (PEMMT) are extramedullary proliferations of myeloid cells occurring in the absence of an antecedent myeloproliferative disorder.
  • They have predilection for the skin, lymph nodes, central nervous system, and small intestine.
  • Treatment with systemic chemotherapy and local radiotherapy rendered a complete remission.
  • PEMMT of the breast is a poorly recognized entity whose diagnosis frequently challenges both the pathologist and the oncologist.
  • Given the small number of patients reported no optimal treatment has been defined, but systemic chemotherapy similar to that given for acute myeloid leukemia with or without local radiotherapy may result in long remissions and avoid the progression to overt acute myeloid leukemia.
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Neoplasm Invasiveness. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12768322.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


20. Yamanaka H, Mizushima T, Mikata S, Ito T, Nonaka K, Ide H, Michiura T, Kainuma S, Iwase K: [Peritoneal dissemination from gastrointestinal stromal tumor of small intestine responding completely to imatinib mesylate (STI 571)]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2125-8
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal dissemination from gastrointestinal stromal tumor of small intestine responding completely to imatinib mesylate (STI 571)].
  • The prognosis of metastatic or recurrent GISTs is poor, because these tumors resist chemotherapy and radiotherapy.
  • We report a patient with recurrent GIST who underwent molecularly targeted therapy with imatinib, a novel oral tyrosine kinase inhibitor.
  • The patient had a history of jejunostomy with colostomy for intestinal GIST.
  • The abdominal mass was phi3 x 3.5 cm in size with ascites at Douglas, as determined by computed tomography, and was diagnosed as a peritoneal relapse of GIST.
  • Treatment with imatinib daily was started.
  • After 1 month of treatment with imatinib, reduction of the abdominal tumor began to be recognized on palpation.
  • Computed tomographic scanning at 11 months revealed that the tumor had completely disappeared.
  • The major side effect was drug eruption,which was easily manageable with 2 weeks drug holidays.
  • Imatinib shows promise as a safe and effective drug for the treatment of patients with recurrent GISTs.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Jejunal Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Benzamides. Drug Administration Schedule. Humans. Imatinib Mesylate. Male. Middle Aged. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352942.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


21. Boinpally RR, Polin L, Zhou SL, Jasti BR, Wiegand RA, White K, Kushner J, Horwitz JP, Corbett TH, Parchment RE: Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors. Cancer Chemother Pharmacol; 2003 Jul;52(1):25-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors.
  • PURPOSE: To compare the pharmacokinetics and tissue distribution (both normal and tumor) of cryptophycin 52 (C-52) and its putative chlorohydrin prodrug cryptophycin 55 (C-55) in a murine model and to investigate a possible mechanism behind the superior activity of C-55.
  • METHODS: Mammary adenocarcinoma 16/c tumor-bearing mice were treated with an i.v. bolus of 11 mg/kg C-52 or 38 mg/kg C-55 in Cremophor-alcohol.
  • At predetermined time intervals, C-52 and C-55 concentrations in plasma, liver, kidney, small intestine and tumors were measured using a previously described HPLC method.
  • Tissue (both normal and tumor) to plasma ratios as a function of time were also calculated for comparison.
  • RESULTS: Both C-52 and C-55 were rapidly distributed into different tissues including tumors following i.v. administration.
  • However, the affinities of these compounds towards different tissues were different.
  • Thus, the half-lives (minutes) of C-55 were in the decreasing order liver (725), intestine (494), tumor (206), kidney (62) and plasma (44), whereas the AUC values (microg x min/ml) were in the order tumor (9077), liver (7734), kidney (6790), plasma (2372) and intestine (2234).
  • For C-52, the half-lives (minutes) were in the decreasing order liver (1333), kidney (718), intestine (389), tumor (181) and plasma (35), and the AUC values (microg x min/ml) were in the order kidney (1164), liver (609), intestine (487), plasma (457) and tumor (442).
  • The relative exposures to C-52 after i.v. injection of C-55 were plasma 3.9%, tumor 80.8%, kidney 3.4%, liver 1.1% and intestine 2.8%.
  • Although plasma exposure to C-52 following C-55 administration was relatively small, the use of C-55 to deliver C-52 increased the retention of C-52 and its AUC in tumor compared to direct injection of C-52.
  • Simultaneously, this approach shortened C-52 retention in all normal tissues studied.
  • CONCLUSIONS: The distribution of C-55 and its bioconversion to C-52 in different organs and tumor tissue observed in this study suggest the ability of C-55 to target tumor tissue, creating a depot of C-52 in tumor.
  • Increased C-52 exposure of tumor, with concomitant decreased exposure of normal tissue, is a contributing factor to the superior activity of C-55 versus C-52.
  • However, except in the case of tumor tissue in which 81% of C-55 converts to C-52, only a minor amount of C-55 may serve as a prodrug for C-52, whereas the majority is handled by the biosystem through a different route of elimination.
  • Tissue distribution combined with rate of conversion may be an important determinant of the relative effectiveness of other epoxide-chlorohydrin pairs of cryptophycins.
  • [MeSH-major] Depsipeptides. Lactams / pharmacokinetics. Lactones / pharmacokinetics. Mammary Neoplasms, Experimental / drug therapy. Peptides, Cyclic / pharmacokinetics
  • [MeSH-minor] Animals. Area Under Curve. Disease Models, Animal. Female. Half-Life. Humans. Metabolic Clearance Rate. Mice. Tissue Distribution. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12739061.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01-CA62487; United States / NCI NIH HHS / CA / U19-CA53001
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Depsipeptides; 0 / Lactams; 0 / Lactones; 0 / Peptides, Cyclic; 0 / cryptophycin 52; 0 / cryptophycin 55
  •  go-up   go-down


22. Debono M, Hon LQ, Bax N, Blakeborough A, Newell-Price J: Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogs. J Clin Endocrinol Metab; 2008 May;93(5):1860-4
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT AND OBJECTIVES: We were referred a patient with metastatic well-differentiated endocrine tumor of the small intestine (midgut carcinoid) in whom asymptomatic sc gluteal nodules had been identified on routine abdominal computed tomography and labeled as metastases.
  • METHODS: Routine abdominal computed tomography scans of 56 patients with metastatic midgut carcinoid were analyzed by two independent radiologists, blinded to treatment status (depot somatostatin analogs).
  • RESULTS: No nodules were detected in 13 patients not on depot somatostatin therapy.
  • Nodules were found in 29 of 43 patients (67%) on somatostatin analog therapy: 16 of 22 patients on lanreotide Autogel, five of 12 patients on octreotide LAR only, and eight of nine patients who had been treated with both somatostatin analogs.
  • Presence of nodules was significantly associated with total number of injections (P = 0.024), duration on treatment (P = 0.022), and cumulative dose of lanreotide Autogel (P < 0.001).
  • CONCLUSION: Patients with metastatic midgut carcinoid tumors have large numbers of asymptomatic sc nodules in the gluteal area when on either depot somatostatin analog, but these resolve over time.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Carcinoid Tumor / drug therapy. Intestinal Neoplasms / drug therapy. Octreotide / adverse effects. Peptides, Cyclic / adverse effects. Radiography, Abdominal. Somatostatin / analogs & derivatives
  • [MeSH-minor] Buttocks. Cross-Sectional Studies. Delayed-Action Preparations. Humans. Neoplasm Metastasis. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303072.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Delayed-Action Preparations; 0 / Peptides, Cyclic; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


23. Takashima M, Igaki N, Matsuda T, Ohyama M, Kanda S, Tamada F, Goto T: Malignant gastrointestinal stromal tumor of the small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate. Intern Med; 2005 Feb;44(2):114-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant gastrointestinal stromal tumor of the small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate.
  • We describe a patient who had a metastatic gastrointestinal stromal tumor (GIST) after previous failed extensive therapy, including multiple surgeries and hepatic artery embolization.
  • Within a few months of starting administration of imatinib mesylate, the patient exhibited a clinical response with grade 3 neutropenia, when pulmonary tuberculosis developed.
  • It is unclear whether or not pulmonary tuberculosis may be induced by imatinib mesylate treatment, but caution is warranted in immunocompromised GIST patients.
  • This is the first report of tuberculosis associated with neutropenia during imatinib mesylate treatment.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Gastrointestinal Stromal Tumors / complications. Jejunal Neoplasms / complications. Leiomyosarcoma / complications. Piperazines / adverse effects. Pyrimidines / adverse effects. Tuberculosis, Pulmonary / complications
  • [MeSH-minor] Administration, Oral. Antitubercular Agents / therapeutic use. Benzamides. Combined Modality Therapy. Digestive System Surgical Procedures. Fatal Outcome. Humans. Imatinib Mesylate. Laparotomy. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Neutropenia / chemically induced. Neutropenia / complications. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750270.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antitubercular Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


24. Huang CC, Yang CY, Lai IR, Chen CN, Lee PH, Lin MT: Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era. World J Surg; 2009 Apr;33(4):828-34
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor of the small intestine: a clinicopathologic study of 70 cases in the postimatinib era.
  • BACKGROUND: The small intestine, after the stomach, is the second most common primary site for gastrointestinal stromal tumors (GISTs).
  • This study aimed to identify clinicopathologic prognostic factors of tumor recurrence and survival and to analyze the influence of imatinib and sunitinib for small-intestine GISTs.
  • METHODS: We reviewed the surgical experience of patients with small-intestine GISTs at National Taiwan University Hospital from January 1995 to March 2007.
  • We analyzed the perioperative clinicopathologic data and treatment course.
  • The tumor was local in 43 patients, advanced in 21 patients, and 6 had metastasis.
  • The median size of the tumor was 6.5 cm.
  • There were 19 patients with recurrent disease and 6 patients died of intestinal GISTs.
  • According to multivariate analysis for disease recurrence, only invasion status, tumor size, and mitotic rate are significant (P=0.007, 0.035, 0.007 respectively).
  • CONCLUSIONS: The invasion status, size, and mitotic rate of tumor involve higher risk of recurrence and poor survival in small-intestine GISTs.
  • The patients with recurrent small-intestine GISTs may have a lower mortality rate after using imatinib and sunitinib.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Intestinal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Disease-Free Survival. Duodenal Neoplasms / drug therapy. Duodenal Neoplasms / pathology. Female. Gastrointestinal Agents / therapeutic use. Humans. Ileal Neoplasms / drug therapy. Ileal Neoplasms / pathology. Infliximab. Jejunal Neoplasms / drug therapy. Jejunal Neoplasms / pathology. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Ann Surg Oncol. 2001 Jan-Feb;8(1):50-9 [11206225.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):477-89 [16625094.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Dig Surg. 2008;25(3):208-12 [18577866.001]
  • [Cites] Am Surg. 2006 Aug;72(8):719-22; discussion 722-3 [16913316.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Am J Clin Pathol. 1997 Dec;108(6):641-51 [9384445.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):407-16 [9130987.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] Mod Pathol. 1997 Mar;10(3):200-9 [9071727.001]
  • [Cites] BMC Gastroenterol. 2006 Oct 24;6:29 [17062131.001]
  • [Cites] J Formos Med Assoc. 2005 Dec;104(12):905-12 [16607447.001]
  • (PMID = 19198935.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; B72HH48FLU / Infliximab
  •  go-up   go-down


25. Biliotti G, Martini F, Vaggelli L, Messerini L, Colagrande S, Pupi A, Seghi P: Multiple effects of somatostatin analogs verified in three cases of metastasized neuroendocrine tumors of the gastroenteropancreatic system. Tumori; 2006 Mar-Apr;92(2):170-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple effects of somatostatin analogs verified in three cases of metastasized neuroendocrine tumors of the gastroenteropancreatic system.
  • AIMS AND BACKGROUND: In neuroendocrine tumors of the gastroenteropancreatic (GEP) system, radiolabeled analogs of somatostatin (SST) are useful to the surgeon in different phases of treatment: preoperatively, to identify the lesion with somato-statin receptor scintigraphy (SRS), intraoperatively for localization using a hand-held gamma probe, and postoperatively acting directly to eliminate any residual tumor cells.
  • Additional features of these analogs that are of value in treating such GEP tumors include their antiproliferative potential, which is in the process of being verified, and, above all, their anti-secretory action, so effective in symptom control.
  • In this study the authors, based on their own experience, evaluate the effectiveness of SST analogs in treating GEP endocrine tumors.
  • In case 1, an insulinoma, the patient underwent four surgical procedures for ablation of the pancreatic tumor and of hepatic and lymph node metastases in addition to local radiofrequency treatment and radiometabolic therapy.
  • Case 2 was a carcinoid tumor of the small intestine with hepatic metastases, managed by ileal resection, local radiofrequency treatment and receptor-mediated radionuclide therapy.
  • In case 3, a non-functioning pancreatic carcinoma with liver and lymph node metastases, the patient underwent four surgical procedures, hepatic chemoembolization, antiproliferative treatment using octreotide (OCT) and metabolic radionuclide therapy.
  • RESULTS: In all three cases SRS proved highly sensitive in the early detection of even the smallest recurrences.
  • There was uncertainty, however, regarding the effectiveness of therapy with radiolabeled SST analogs.
  • Hepatic metastases from the carcinoid were completely unresponsive, but in the case of the insulinoma, the hepatic metastases showed necrosis following treatment, while lymph node metastases were unaffected.
  • In the case of the non-functioning carcinoma, there was a correlation between treatment and a marked improvement in the patient's clinical condition, although the appearance of the lesions themselves remained unchanged.
  • The merits of radiometabolic therapy, on the other hand, were unclear, a finding reported elsewhere in the literature, and in the only case treated by prolonged OCT treatment, no antiproliferative action was observed.
  • The diagnostic usefulness of SRS was thus confirmed and it appears likely that radiolabeled analogs used intraoperatively for tumor localization will prove equally of value.
  • The effectiveness of receptor-mediated radionuclide therapy is still in the process of being verified.
  • Based on the expectation of analogs with an universal affinity for SST receptors (sst), it is reasonable to look forward to a significant increase in the efficacy of this type of therapy.
  • [MeSH-major] Digestive System Neoplasms / diagnosis. Digestive System Neoplasms / drug therapy. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / drug therapy. Somatostatin / therapeutic use
  • [MeSH-minor] Carcinoid Tumor / diagnosis. Carcinoid Tumor / drug therapy. Carcinoma / diagnosis. Carcinoma / drug therapy. Female. Gamma Rays. Humans. Insulinoma / diagnosis. Insulinoma / drug therapy. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / drug therapy. Radionuclide Imaging. Sensitivity and Specificity. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16724698.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 51110-01-1 / Somatostatin
  •  go-up   go-down


26. Eliakim R: Video capsule endoscopy of the small bowel. Curr Opin Gastroenterol; 2010 Mar;26(2):129-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Video capsule endoscopy of the small bowel.
  • PURPOSE OF REVIEW: It is now over 8 years since small bowel capsule endoscopy (SBCE) was first introduced to the gastrointestinal community.
  • SBCE has become a first-line tool to detect abnormalities in the small bowel, as all other imaging technologies are rather ineffective, or very tedious.Indications for SBCE include obscure gastrointestinal bleeding, suspected small bowel tumor, suspected Crohn's disease, surveillance of inherited polyposis syndromes, drug-induced small bowel injury or any abnormal small bowel imaging and new ones are emerging like small bowel motility.
  • Since most of the articles in the literature relate to the PillCam small bowel capsule the data presented will refer mainly to this capsule endoscopy.
  • SUMMARY: SBCE has shed new light into our knowledge of the small bowel, paving the way for new modalities to come.
  • [MeSH-major] Capsule Endoscopes. Capsule Endoscopy / methods. Intestinal Diseases / diagnosis. Intestine, Small / pathology
  • [MeSH-minor] Crohn Disease / diagnosis. Crohn Disease / therapy. Equipment Design. Female. Gastrointestinal Hemorrhage / diagnosis. Gastrointestinal Hemorrhage / therapy. Humans. Male. Patient Selection. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20145540.001).
  • [ISSN] 1531-7056
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


27. Fukushima M, Suzuki N, Emura T, Yano S, Kazuno H, Tada Y, Yamada Y, Asao T: Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2'-deoxyribonucleosides. Biochem Pharmacol; 2000 May 15;59(10):1227-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro inhibition studies of TPI using a thymidine analogue, 5-trifluoromethyl-2'-deoxyuridine (F(3)dThd), as the substrate demonstrated that F(3)dThd phosphorolytic activity was inhibited markedly by TPI (1 x 10(-6) M) in extracts from the liver, small intestine, and tumors of humans, from the liver and small intestine of cynomolgus monkeys, and from the liver of rodents, but not from the liver or small intestine of dogs or the small intestine of rodents, suggesting that the distribution of TPase differs between humans and animal species, and that TPI could contribute to the modulation of TPase in humans.
  • In monkeys, the maximum concentration (C(max)) and the area under the concentration-time curve (AUC) after oral F(3)dThd alone were 0.23 microg/mL and 0.28 microg. hr/mL, respectively, but markedly increased to 15.18 microg/mL (approximately 70-fold) and 28.47 microg. hr/mL (approximately 100-fold), respectively, when combined with equimolar TPI.
  • [MeSH-minor] Administration, Oral. Animals. Antineoplastic Agents / chemistry. Antineoplastic Agents / pharmacology. Dogs. Drug Synergism. Female. Humans. Idoxuridine / blood. Idoxuridine / pharmacokinetics. Macaca fascicularis. Male. Mice. Mice, Inbred ICR. Mice, Nude. Neoplasm Transplantation. Neoplasms, Experimental / drug therapy. Placenta / enzymology. Recombinant Proteins / antagonists & inhibitors. Structure-Activity Relationship. Thymidine / analogs & derivatives. Trifluridine / blood. Trifluridine / pharmacokinetics. Trifluridine / therapeutic use

  • Hazardous Substances Data Bank. IDOXURIDINE .
  • Hazardous Substances Data Bank. Trifluridine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10736423.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / 5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloride; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Pyrrolidines; 0 / Recombinant Proteins; 56HH86ZVCT / Uracil; EC 2.4.2.4 / Thymidine Phosphorylase; LGP81V5245 / Idoxuridine; RMW9V5RW38 / Trifluridine; VC2W18DGKR / Thymidine
  •  go-up   go-down


28. Maity P, Chakraborty S, Bhattacharya P: A general survey of glutamine level in different tissues of murine solid tumor bearing mice before and after therapy with purified glutaminase. J Exp Clin Cancer Res; 2000 Jun;19(2):161-4
Hazardous Substances Data Bank. Glutamine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A general survey of glutamine level in different tissues of murine solid tumor bearing mice before and after therapy with purified glutaminase.
  • Distribution of glutamine level in different tissues of tumor bearing mice such as brain, liver, kidney, spleen, large and small intestine and the tumor itself were studied in three solid tumor models, viz, Ehrlich ascites carcinoma, Sarcoma-180 and methylcholanthrene induced carcinoma.
  • Tumor bearing mice were subjected to therapy for 7 days with the glutaminase purified from malignant S-180 cell.
  • The results exhibit a significant decrease in tumor burden after enzyme therapy.
  • Host tissue glutamine levels were significantly elevated in tumor bearing untreated mice in comparison to the normal ones, while significant lower values were obtained after enzyme therapy.
  • It therefore appears that elevated levels of glutamine in host tissue are associated with the tumor burden.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / drug therapy. Glutaminase / therapeutic use. Glutamine / metabolism. Sarcoma 180 / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Brain / metabolism. Intestines / metabolism. Kidney / metabolism. Liver / metabolism. Male. Methylcholanthrene / toxicity. Mice. Spleen / metabolism. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. 3-Methylcholanthrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10965812.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ITALY
  • [Chemical-registry-number] 0RH81L854J / Glutamine; 56-49-5 / Methylcholanthrene; EC 3.5.1.2 / Glutaminase
  •  go-up   go-down






Advertisement